Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT01767129 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyskinesia
Parkinson's Disease

Interventions

DRUG: AVP-923-45
DRUG: Placebo

Sponsor

Avanir Pharmaceuticals

Collaborators

[object Object]